Dean Li, Merck

Dean Li in­vites an­oth­er un­der-the-radar biotech to Mer­ck­'s deal­mak­ing ta­ble as Am­ath­us signs neu­rode­gen­er­a­tion pact

Less than three months since tak­ing over from Roger Perl­mut­ter, new Mer­ck R&D chief Dean Li con­tin­ues to wheel and deal.

Li and the Mer­ck team have agreed to a new col­lab­o­ra­tion with lit­tle-known biotech Am­ath­us Ther­a­peu­tics, promis­ing an undis­closed up­front amount in ad­di­tion to an op­tion to ac­quire the com­pa­ny. Should the op­tion be ex­er­cised, Am­ath­us would be in line for up to $500 mil­lion in mile­stones per pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.